Asia Pacific Oncology Based Molecular Diagnostics Market Size - Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

The market covers molecular assays used to identify oncogenic mutations, fusions, amplifications, and expression signatures that inform cancer diagnosis and treatment. Valued at roughly USD 3.89 billion in 2025, Asia Pacific represents the largest regional segment of the global oncology molecular diagnostics industry. Growth is concentrated in genomics-based tests, particularly NGS panels for solid tumors and hematologic malignancies.

• •Market size in 2025 is approximately USD 3.89 billion, with a forecast CAGR of around 7.75%.
• •The region accounts for the largest share of the global oncology molecular diagnostics market.
• •NGS and PCR-based companion diagnostics dominate current test volumes.

Cancer incidence is rising sharply across Asia Pacific, with lung, colorectal, breast, and gastric cancers among the most prevalent, creating sustained demand for molecular profiling. Health authorities in China, Japan, South Korea, and Australia are expanding reimbursement for companion diagnostics that match patients to targeted therapies. National genomics initiatives, such as China's precision medicine programs and Japan's national cancer genome screening, are accelerating clinical adoption of molecular testing.

• •Increasing cancer burden and earlier screening programs are expanding test volumes.
• •Broader reimbursement for companion diagnostics is improving patient access.
• •Government-backed precision medicine initiatives are funding NGS infrastructure.

By technology, the market spans PCR, NGS, fluorescence in situ hybridization (FISH), and immunohistochemistry-based molecular assays, with NGS capturing the fastest-growing share. By application, solid tumor testing represents the largest segment, while liquid biopsy and hematologic malignancy panels are expanding quickly. China is the dominant country market, followed by Japan, South Korea, Australia, and India.

• •Solid tumor diagnostics hold the largest application share; liquid biopsy is the fastest-growing segment.
• •China, Japan, and South Korea lead regional revenue, while India and Southeast Asia show the highest growth rates.
• •Hospital-based laboratories are the primary end users, followed by independent reference labs.

What are the recent trends and outlook?

Liquid biopsy assays that analyze circulating tumor DNA are moving from research into routine clinical use, particularly for monitoring treatment response and detecting resistance mutations. The integration of artificial intelligence and machine learning into variant interpretation is shortening turnaround times and improving test accuracy. Over the medium term, broader payer coverage, falling sequencing costs, and growing adoption of multi-cancer early detection panels are expected to sustain above-average growth across the region.

• •Liquid biopsy and ctDNA-based monitoring are the fastest-growing test categories.
• •AI-driven variant interpretation is being adopted by major reference laboratories.
• •Multi-cancer early detection panels are entering pilot programs in China, Japan, and Australia.